VENEZE peptide hair serum versus 2% topical minoxidil for androgenetic alopecia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, parallel-group comparison of a peptide-based topical serum against standard 2% topical minoxidil in adults with androgenetic alopecia. Participants are randomly assigned to one of the two treatments and followed over a defined treatment period with regular in-person visits. Primary outcomes are objective measures of hair growth, including hair density and hair thickness, and secondary outcomes include safety, tolerability, and patient-reported measures. The protocol requires consistent hair styling and measures to limit confounding factors affecting hair growth.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female participants aged ≥18 years.
* Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
* Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
* Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
* Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
* Able to attend all scheduled visits during the 24-week study period.

Exclusion Criteria:

* Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
* History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
* Psychiatric disorders or other conditions that may affect participant safety or compliance.
* Pregnant or breastfeeding women.

Hair and scalp-related exclusions:

* Diffuse hair thinning involving the occipital area.
* Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
* History of hair transplantation at any time or hair extensions within 6 months prior to screening.
* Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.
* Use of light/laser therapy on the scalp within 3 months prior to screening.
* Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.
* Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.
* Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.

Medication-related exclusions:

* Known hypersensitivity to study-related products or ingredients.
* Use of dutasteride within 12 months prior to screening.
* Use of systemic cytotoxic agents.
* Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).
* Use within 6 months prior to screening of:

  * Minoxidil (topical or oral)
  * Finasteride (topical or oral)
  * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)
  * Prostaglandin analogs applied to the scalp
  * Estrogen or progesterone topical preparations
  * Tamoxifen
  * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)
  * Drugs associated with hair loss (e.g., valproic acid)
* Participation in another clinical trial within 1 month prior to screening or during this study.

Where it's running

• Institute of dermatology
  Bangkok, Bangkok, Thailand Recruiting
• Institute of Dermatology
  Bangkok, Thailand Recruiting

Study contacts

• Principal investigator: Chinmanat Lekhavat, MD, PhD — Institute of Dermatology
• Study coordinator: Chinmanat Lekhavat, MD, PhD
• Email: chinmanat@inderm.org
• Phone: 66023545222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exosome therapy for male pattern baldness

  This trial tests whether injecting hUCMSC-derived exosomes into the scalp can promote hair regrowth in men with androgenetic alopecia, compared with a placebo.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07693244

• Multi-omics view of androgenetic alopecia in scalp tissue

  This study tests a multi-omics approach to understand hair follicle biology in men with androgenetic alopecia by comparing affected and healthy scalp tissue.

  Recruiting The First Affiliated Hospital of Xinxiang Medical College · Xinxiang, Henan · NCT07603544

• Topical Lactobacillus reuteri for hair loss due to androgenetic alopecia

  This trial will test whether applying a topical Lactobacillus reuteri solution can increase hair count and improve hair quality in adults (18–60) with androgenetic alopecia over 12 months.

  Recruiting Phase 2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07370519

• OLX72021 for men with male-pattern hair loss

  This research will test whether OLX72021 is safe and may help men aged 18 to 59 with mild to moderate male-pattern hair loss.

  Recruiting Phase 1/2 Olix Pharmaceuticals, Inc. · Botany, New South Wales and 7 other locations · NCT07327359

• ABS-201 for improving hair growth in healthy adults and people with androgenetic alopecia

  This trial will test whether ABS-201 is safe and helps hair grow in healthy adults and in men and women with androgenetic alopecia.

  Recruiting at 5 sites Phase 1/2 Absci Pty Ltd. · Sydney, New South Wales and 4 other locations · NCT07317544

• Thulium laser with growth-factor serum (with or without LED) for androgenetic hair loss

  This trial tests whether thulium laser plus a growth-factor serum, with or without added LED light, can improve hair growth in adults with androgenetic alopecia.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07079657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.